Adams C, Awad G, Rathbone J, Thornley B, Soares-Weiser K
Cochrane Database Syst Rev. 2014; (1):CD000284.
PMID: 24395698
PMC: 10640712.
DOI: 10.1002/14651858.CD000284.pub3.
Prinssen E, Ellenbroek B, Cools A
Br J Pharmacol. 1994; 112(3):769-74.
PMID: 7921601
PMC: 1910211.
DOI: 10.1111/j.1476-5381.1994.tb13145.x.
Barber H, Kitteringham N, Petrie J
Br J Pharmacol. 1982; 77(4):667-77.
PMID: 7150874
PMC: 2044668.
DOI: 10.1111/j.1476-5381.1982.tb09345.x.
Kendall M, JACK D, Laugher S, Lobo J, Rolf Smith S
Br J Clin Pharmacol. 1984; 18(3):331-5.
PMID: 6487472
PMC: 1463644.
DOI: 10.1111/j.1365-2125.1984.tb02472.x.
Wood A, Feely J
Clin Pharmacokinet. 1983; 8(3):253-62.
PMID: 6342901
DOI: 10.2165/00003088-198308030-00004.
The effect of propranolol on CSF amine metabolites in psychiatric patients.
King D, Cooper S, Liddle J
Br J Clin Pharmacol. 1983; 15(3):331-7.
PMID: 6189502
PMC: 1427775.
DOI: 10.1111/j.1365-2125.1983.tb01507.x.
Failure of 'therapeutic' doses of beta-adrenoceptor antagonists to alter the disposition of tolbutamide and lignocaine.
Miners J, Wing L, Lillywhite K, Smith K
Br J Clin Pharmacol. 1984; 18(6):853-60.
PMID: 6152176
PMC: 1463673.
DOI: 10.1111/j.1365-2125.1984.tb02555.x.
Prediction of metabolic drug interactions involving beta-adrenoceptor blocking drugs.
Park B
Br J Clin Pharmacol. 1984; 17 Suppl 1:3S-10S.
PMID: 6146338
PMC: 1463283.
DOI: 10.1111/j.1365-2125.1984.tb02422.x.
Dose dependent changes in propranolol half life when used as an adjunct to neuroleptic treatment.
Staniforth D, Yorkston N, Zaki S
Psychopharmacology (Berl). 1982; 76(1):62-5.
PMID: 6123130
DOI: 10.1007/BF00430757.
Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists.
Bax N, Lennard M, Tucker G
Br J Clin Pharmacol. 1981; 12(6):779-84.
PMID: 6122461
PMC: 1401937.
DOI: 10.1111/j.1365-2125.1981.tb01306.x.
Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists in related to their lipid solubility.
Deacon C, Lennard M, Bax N, Woods H, Tucker G
Br J Clin Pharmacol. 1981; 12(3):429-31.
PMID: 6117306
PMC: 1401820.
DOI: 10.1111/j.1365-2125.1981.tb01240.x.
Selectivity and dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man.
Miners J, Wing L, Lillywhite K, Robson R
Br J Clin Pharmacol. 1985; 20(3):219-23.
PMID: 4041342
PMC: 1400697.
DOI: 10.1111/j.1365-2125.1985.tb05064.x.
Adverse reactions and interactions with beta-adrenoceptor blocking drugs.
Lewis R, McDevitt D
Med Toxicol. 1986; 1(5):343-61.
PMID: 2878346
DOI: 10.1007/BF03259848.
Inhibitory effects of neuroleptics on debrisoquine oxidation in man.
Syvalahti E, Lindberg R, Kallio J, de Vocht M
Br J Clin Pharmacol. 1986; 22(1):89-92.
PMID: 2874826
PMC: 1401082.
The impairment of lignocaine clearance by propranolol--major contribution from enzyme inhibition.
Bax N, Tucker G, Lennard M, Woods H
Br J Clin Pharmacol. 1985; 19(5):597-603.
PMID: 2860914
PMC: 1463847.
DOI: 10.1111/j.1365-2125.1985.tb02686.x.
The effect of propranolol on paracetamol metabolism in man.
Baraka O, Truman C, Ford J, Roberts C
Br J Clin Pharmacol. 1990; 29(2):261-4.
PMID: 2306420
PMC: 1380095.
DOI: 10.1111/j.1365-2125.1990.tb03631.x.
The effects of beta-adrenoceptor antagonists and levomepromazine on the metabolic ratio of debrisoquine.
Kallio J, Huupponen R, Seppala M, Sako E, IISALO E
Br J Clin Pharmacol. 1990; 30(4):638-43.
PMID: 1981321
PMC: 1368259.
DOI: 10.1111/j.1365-2125.1990.tb03827.x.
